West, a manufacturer of injectable drug delivery systems, has entered into a collaboration agreement with Janssen Biotech to develop new self-injection technology, designed to deliver pharmaceutical and biologic drug products.
Under the agreement, West will be responsible for co-developing and manufacturing of the product, under the name, SelfDose.
West said the new SelfDose injection technology complements its ConfiDose and SmartDose injection technologies, and offers a solution for improved manual injection.
West chairman and CEO Donald Morel said the company looks forward to work together to commercialize the SelfDose injection technology, providing manufacturing, development and regulatory support through the remainder of the process.
"We look forward to working with Janssen to help them meet their business goals to restore health and serve patients," Morel added.
